| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
TG-2-IN-1 targets transglutaminase-2 (TGM-2), a calcium-dependent enzyme that catalyzes the formation of covalent cross-links between proteins through transamidation of glutamine and lysine residues. TGM-2 is involved in diverse biological processes including apoptosis, cell adhesion, differentiation, and extracellular matrix stabilization. By inhibiting TGM-2, TG-2-IN-1 can modulate these processes, making it relevant for studying diseases where TGM-2 is dysregulated, such as cancer, fibrosis, and neurodegenerative disorders.
|
|---|---|
| ln Vitro |
In vitro activity data for TG-2-IN-1 are limited in the literature. As a potent TGM-2 inhibitor, it is expected to inhibit TGM-2 enzymatic activity in cell-free and cell-based assays. The compound's ability to inhibit TGM-2-mediated protein cross-linking can be assessed using biochemical assays. However, specific IC₅₀ values and detailed activity profiles against TGM-2 and related transglutaminases are not extensively documented.
|
| ln Vivo |
In vivo activity data for TG-2-IN-1 are not extensively documented. Based on its TGM-2 inhibitory mechanism, the compound has potential applications in studying myopia, cancer, neurological disorders, and immune system disorders. However, specific in vivo efficacy data in animal models are limited. The compound is primarily used as a research tool for studying TGM-2 biology.
|
| Enzyme Assay |
The non-cellular enzyme/receptor binding assay for TG-2-IN-1 typically involves measuring TGM-2 enzymatic activity using a fluorometric or colorimetric substrate. TGM-2 enzyme is incubated with a suitable substrate, such as a glutamine-containing peptide and a fluorescently labeled amine donor, in the presence of calcium ions. TG-2-IN-1 is added at various concentrations, and the inhibition of enzyme activity is measured. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for TG-2-IN-1 typically use cell lines relevant to the disease being studied, such as cancer cell lines or neuronal cells. Cells are treated with various concentrations of TG-2-IN-1, and TGM-2 activity is assessed by measuring the formation of cross-linked proteins or by using activity-based probes. Cell viability, proliferation, apoptosis, and differentiation are evaluated using standard assays such as MTT, flow cytometry, and immunoblotting for relevant biomarkers.
|
| Animal Protocol |
In vivo animal studies for TG-2-IN-1 are not extensively documented. Based on its TGM-2 inhibitory mechanism, typical study designs would involve animal models of myopia, cancer, or neurological disorders. TG-2-IN-1 would be administered via appropriate routes depending on the target tissue. Efficacy endpoints would include disease-specific parameters such as axial length (for myopia), tumor volume (for cancer), or behavioral assessments (for neurological disorders).
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TG-2-IN-1 are not extensively characterized. As a small molecule with molecular weight 220.72 and good water solubility, it is expected to have reasonable bioavailability. The compound's half-life, clearance, volume of distribution, and protein binding are not well documented. Further pharmacokinetic studies would be needed to characterize its ADME properties.
|
| Toxicity/Toxicokinetics |
Toxicological data for TG-2-IN-1 are limited. As a research-grade compound, comprehensive toxicology studies including acute and chronic toxicity, genotoxicity, and organ-specific toxicity are not available in the literature. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
1,3-Dimethyl-2-[(2-oxopropyl)thio]imidazolium chloride is an organochloride whose cationic component is 1,3-dimethyl-2-[(2-oxopropyl)thio]imidazolium. It is an EC 2.3.2.13 (protein-glutamine-γ-glutamyltransferase) inhibitor. It contains 1,3-dimethyl-2-[(2-oxopropyl)thio]imidazolium.
See also: 1,3-dimethyl-2-((2-oxopropyl)thio)imidazolium (note moved to). TG-2-IN-1 is a research-grade compound intended for laboratory use only. It is not approved for clinical use as a therapeutic agent. Its primary applications include studying the role of transglutaminase-2 in various diseases, investigating TGM-2 biology, and exploring the therapeutic potential of TGM-2 inhibitors. The compound is also known as Compound D003 and is used in myopia research. |
| Molecular Formula |
C8H13N2OS+
|
|---|---|
| Molecular Weight |
185.26662
|
| Exact Mass |
220.044
|
| CAS # |
135273-74-4
|
| PubChem CID |
196876
|
| Appearance |
Off-white to light brown solid powder
|
| LogP |
1.332
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
164
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NFZZAUJDSJWLTQ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C8H13N2OS.ClH/c1-7(11)6-12-8-9(2)4-5-10(8)3;/h4-5H,6H2,1-3H3;1H/q+1;/p-1
|
| Chemical Name |
1-(1,3-dimethylimidazol-1-ium-2-yl)sulfanylpropan-2-one;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~453.06 mM)
DMSO : ~25 mg/mL (~113.27 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3975 mL | 26.9876 mL | 53.9753 mL | |
| 5 mM | 1.0795 mL | 5.3975 mL | 10.7951 mL | |
| 10 mM | 0.5398 mL | 2.6988 mL | 5.3975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
